Cargando…

Bone Strength/Bone Mass Discrepancy in Glucocorticoid‐Treated Adult Mice

Glucocorticoids increase bone fragility in patients in a manner that is underestimated by bone mass measurement. This study aimed to determine if the adult mouse could model this bone strength/bone mass discrepancy. Forty‐two 13‐week‐old BALB/cJ mice were randomized into vehicle and glucocorticoid g...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubrovsky, Alanna M., Nyman, Jeffrey S., Uppuganti, Sasidhar, Chmiel, Kenneth J., Kimmel, Donald B., Lane, Nancy E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990143/
https://www.ncbi.nlm.nih.gov/pubmed/33778319
http://dx.doi.org/10.1002/jbm4.10443
_version_ 1783669020814213120
author Dubrovsky, Alanna M.
Nyman, Jeffrey S.
Uppuganti, Sasidhar
Chmiel, Kenneth J.
Kimmel, Donald B.
Lane, Nancy E
author_facet Dubrovsky, Alanna M.
Nyman, Jeffrey S.
Uppuganti, Sasidhar
Chmiel, Kenneth J.
Kimmel, Donald B.
Lane, Nancy E
author_sort Dubrovsky, Alanna M.
collection PubMed
description Glucocorticoids increase bone fragility in patients in a manner that is underestimated by bone mass measurement. This study aimed to determine if the adult mouse could model this bone strength/bone mass discrepancy. Forty‐two 13‐week‐old BALB/cJ mice were randomized into vehicle and glucocorticoid groups, implanted with vehicle or 6‐methylprednisolone pellets, and necropsied after 60 and 120 days. Bone strength and bone mass/microarchitecture were assessed at the right central femur (CF; cortical‐bone–rich) and sixth lumbar vertebral body (LVB6; trabecular‐bone–rich). Bound water (BW) of the whole right femur was analyzed by proton‐nuclear magnetic resonance ((1)H‐NMR) relaxometry. Data were analyzed by two‐factor ANOVA with time (day 60 and day 120) and treatment (vehicle and glucocorticoid) as main effects for all data. Significant interactions were further analyzed with a Tukey's post hoc test. Most bone strength measures in the CF were lower in the glucocorticoid group, regardless of the duration of treatment, with no time × treatment interaction. However, bone mass measures in the CF showed a significant time × treatment interaction (p = 0.0001). Bone strength measures in LVB6 showed a time × treatment interaction (p < 0.02) such that LVB6 strength was lower after 120 days of glucocorticoids compared with 120 days of vehicle treatment. Whole‐femur–BW was lower with both glucocorticoid treatment (p = 0.0001) and time (p < 0.02), with a significant time × treatment interaction (p = 0.005). Glucocorticoid treatment of male BALB/cJ mice resulted in the lowering of bone strength in both cortical and trabecular bone that either appeared earlier or was greater than the treatment‐related changes in bone mass/microarchitecture. The adult mouse may be a good model for investigating the bone strength/mass discrepancy observed in glucocorticoid‐treated patients. © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research.
format Online
Article
Text
id pubmed-7990143
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-79901432021-03-25 Bone Strength/Bone Mass Discrepancy in Glucocorticoid‐Treated Adult Mice Dubrovsky, Alanna M. Nyman, Jeffrey S. Uppuganti, Sasidhar Chmiel, Kenneth J. Kimmel, Donald B. Lane, Nancy E JBMR Plus Original Articles Glucocorticoids increase bone fragility in patients in a manner that is underestimated by bone mass measurement. This study aimed to determine if the adult mouse could model this bone strength/bone mass discrepancy. Forty‐two 13‐week‐old BALB/cJ mice were randomized into vehicle and glucocorticoid groups, implanted with vehicle or 6‐methylprednisolone pellets, and necropsied after 60 and 120 days. Bone strength and bone mass/microarchitecture were assessed at the right central femur (CF; cortical‐bone–rich) and sixth lumbar vertebral body (LVB6; trabecular‐bone–rich). Bound water (BW) of the whole right femur was analyzed by proton‐nuclear magnetic resonance ((1)H‐NMR) relaxometry. Data were analyzed by two‐factor ANOVA with time (day 60 and day 120) and treatment (vehicle and glucocorticoid) as main effects for all data. Significant interactions were further analyzed with a Tukey's post hoc test. Most bone strength measures in the CF were lower in the glucocorticoid group, regardless of the duration of treatment, with no time × treatment interaction. However, bone mass measures in the CF showed a significant time × treatment interaction (p = 0.0001). Bone strength measures in LVB6 showed a time × treatment interaction (p < 0.02) such that LVB6 strength was lower after 120 days of glucocorticoids compared with 120 days of vehicle treatment. Whole‐femur–BW was lower with both glucocorticoid treatment (p = 0.0001) and time (p < 0.02), with a significant time × treatment interaction (p = 0.005). Glucocorticoid treatment of male BALB/cJ mice resulted in the lowering of bone strength in both cortical and trabecular bone that either appeared earlier or was greater than the treatment‐related changes in bone mass/microarchitecture. The adult mouse may be a good model for investigating the bone strength/mass discrepancy observed in glucocorticoid‐treated patients. © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research. John Wiley & Sons, Inc. 2020-12-21 /pmc/articles/PMC7990143/ /pubmed/33778319 http://dx.doi.org/10.1002/jbm4.10443 Text en © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of American Society for Bone and Mineral Research. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Dubrovsky, Alanna M.
Nyman, Jeffrey S.
Uppuganti, Sasidhar
Chmiel, Kenneth J.
Kimmel, Donald B.
Lane, Nancy E
Bone Strength/Bone Mass Discrepancy in Glucocorticoid‐Treated Adult Mice
title Bone Strength/Bone Mass Discrepancy in Glucocorticoid‐Treated Adult Mice
title_full Bone Strength/Bone Mass Discrepancy in Glucocorticoid‐Treated Adult Mice
title_fullStr Bone Strength/Bone Mass Discrepancy in Glucocorticoid‐Treated Adult Mice
title_full_unstemmed Bone Strength/Bone Mass Discrepancy in Glucocorticoid‐Treated Adult Mice
title_short Bone Strength/Bone Mass Discrepancy in Glucocorticoid‐Treated Adult Mice
title_sort bone strength/bone mass discrepancy in glucocorticoid‐treated adult mice
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990143/
https://www.ncbi.nlm.nih.gov/pubmed/33778319
http://dx.doi.org/10.1002/jbm4.10443
work_keys_str_mv AT dubrovskyalannam bonestrengthbonemassdiscrepancyinglucocorticoidtreatedadultmice
AT nymanjeffreys bonestrengthbonemassdiscrepancyinglucocorticoidtreatedadultmice
AT uppugantisasidhar bonestrengthbonemassdiscrepancyinglucocorticoidtreatedadultmice
AT chmielkennethj bonestrengthbonemassdiscrepancyinglucocorticoidtreatedadultmice
AT kimmeldonaldb bonestrengthbonemassdiscrepancyinglucocorticoidtreatedadultmice
AT lanenancye bonestrengthbonemassdiscrepancyinglucocorticoidtreatedadultmice